×
About 25,628 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  7,168 results

Dermatologists share vitiligo breakthrough news with patients
https://www.mdedge.com/dermatology/article/257010/pigmentation-disorders/dermatologists-share-vitiligo-breakthrough-news
Marcia Frellick

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal r...
https://doi.org/10.1080/09546634.2022.2112138
The Journal of Dermatological Treatment; Naeimifar A, Ahmad Nasrollahi S et. al.

Aug 10th, 2022 - Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the effica...

Tapinarof Cream 1%: First Approval.
https://doi.org/10.1007/s40265-022-01748-6
Drugs Keam SJ

Aug 9th, 2022 - Tapinarof cream 1% (VTAMA®) is an aryl hydrocarbon receptor (AhR) agonist that is being developed by Dermavant Sciences Inc. (a subsidiary of Roivant Sciences Inc.) as a once-daily topical treatment for plaque psoriasis and atopic dermatitis. AhR ...

Hand and foot dermatitis in patients referred for patch testing: Analysis of North Amer...
https://doi.org/10.1016/j.jaad.2022.07.035
Journal of the American Academy of Dermatology; Silverberg JI, Patel N et. al.

Aug 9th, 2022 - Dermatitis localized to hands (HD), feet (FD), or both hands and feet (HFD) has multiple etiologies including atopic dermatitis (AD), irritant contact dermatitis (ICD), and allergic contact dermatitis (ACD). Little is known about clinical differen...

Commentary: Conditions Associated with AD, August 2022
https://www.mdedge.com/dermatology/article/256875/atopic-dermatitis/commentary-conditions-associated-ad-august-2022
Jonathan Silverberg, MD, PhD, MPH

Aug 8th, 2022 - Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis (AD) is truly a fascinating disease! Despite the thousands of scientific manuscripts published on AD, more novel insights keep coming about the clinical manifestations and risk factors of this co.

see more →

Guidelines  9 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  504 results see all →

Clinicaltrials.gov  1,043 results

Natural History of Severe Allergic Inflammation and Reactions
https://clinicaltrials.gov/ct2/show/NCT01164241

Aug 5th, 2022 - Allergic inflammation is central to the pathogenesis of allergic diseases, including atopic dermatitis, asthma, allergic rhinitis, and food allergy. These disorders are common, affecting up to 50 million Americans, and their pathophysiology remain...

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05117060

Aug 5th, 2022 - This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it works to treat AD and what the side effects are when compared ...

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05155085

Aug 5th, 2022 - This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately...

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03916081

Aug 4th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream 0.05% or ARQ-151 cream 0.15% or vehicle is applied QD x 4 weeks to adolescent and adult subjects with atopic dermatitis. A subset of subjects will have serial ...

see more →

News  1,513 results

Dermatologists share vitiligo breakthrough news with patients
https://www.mdedge.com/dermatology/article/257010/pigmentation-disorders/dermatologists-share-vitiligo-breakthrough-news
Marcia Frellick

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

'I Shall Harm': When Patients Experience the Nocebo Effect
https://www.medscape.com/viewarticle/979130

Aug 12th, 2022 - I was quite sure I had multiple sclerosis when I was a medical student. I first noticed symptoms during my neurology rotation. All the signs were there: Fatigue that was getting worse in the North Carolina heat (Uhthoff sign!). A tingle running do...

Dupilumab Dose Reduction Successful in Controlled Atopic Dermatitis
https://www.medscape.com/viewarticle/979120

Aug 12th, 2022 - Dupilumab dose reduction appears feasible in patients with controlled atopic dermatitis (AD) who have been on the monoclonal antibody therapy for at least 1 year, according to a recent study. The researchers suggest that the findings, published in...

Baricitinib Reduces Signs and Symptoms of Cyclosporine-Resistant AD Up to 1 Year
https://www.medscape.com/viewarticle/979094

Aug 11th, 2022 - The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) improves signs and symptoms of moderate to severe atopic dermatitis (AD) in patients who fail or cannot tolerate cyclosporine, according to a phase 3 study published in the British Journ...

Commentary: Conditions Associated with AD, August 2022
https://www.mdedge.com/dermatology/article/256875/atopic-dermatitis/commentary-conditions-associated-ad-august-2022
Jonathan Silverberg, MD, PhD, MPH

Aug 8th, 2022 - Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis (AD) is truly a fascinating disease! Despite the thousands of scientific manuscripts published on AD, more novel insights keep coming about the clinical manifestations and risk factors of this co.

see more →

Patient Education  14 results see all →